Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 331
interventional 256
Observational 66
Registry 9

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 159
Biological|Drug 11
Device 8
Drug|Other 8
Drug|placebo 8
Drug|Procedure 7
Biological 6
Device|Drug 5
Procedure 5
Radiation 5
Biological|Drug|Other 4
Other 4
Behavioral 2
Device|Drug|Other 2
Diagnostic Test 2
Dietary Supplement 2
Dietary Supplement|Other 2
Drug|Other|placebo 2
Behavioral|Drug 1
Biological|Device|Procedure 1
Biological|Drug|Other|Procedure 1
Biological|Other|Radiation 1
Biological|Radiation 1
Combination Product|Device 1
Device|Other|Radiation 1
Device|Radiation 1
Diagnostic Test|Drug|Radiation 1
Drug|Genetic|Other 1
Drug|Other|Procedure 1
Drug|Other|Procedure|Radiation 1
Drug|Radiation 1
Procedure|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 113
Italy 18
China 17
Canada 9
France 9
Spain 7
Germany 6
Netherlands 6
United Kingdom 4
United States|Canada 4
Australia 3
Belgium 3
Brazil 3
Korea, Republic of 3
NA 3
Sweden 3
Denmark 2
Japan 2
Poland 2
Switzerland 2
United States|United Kingdom 2
Austria|Germany 1
Austria|Italy 1
Austria|Italy|Spain|United Kingdom 1
Belgium|Denmark|France|Germany|Ireland|Italy|Netherlands|Poland|Spain|United Kingdom 1
Belgium|France|Germany|United Kingdom 1
Colombia 1
Denmark|France|Germany|Italy|Netherlands|Spain|Sweden|United Kingdom 1
Denmark|Norway|Sweden 1
France|Germany|Italy|Netherlands|Poland|Spain|Sweden|United Kingdom 1
France|Germany|Italy|Sweden 1
Germany|Italy|Spain|United Kingdom 1
Greece|Italy|United States|Belgium|Brazil|Canada|France|Germany|Japan|Korea, Republic of|Netherlands|Slovakia|Spain|Sweden|Switzerland|Taiwan|Thailand|United Kingdom 1
Israel 1
Saudi Arabia 1
Slovakia|United States|Australia|Belgium|China|Czechia|France|Hungary|India|Italy|Japan|Norway|Romania|South Africa|Spain 1
Spain|United Kingdom 1
Taiwan 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Colombia|France|Germany|Hong Kong|Korea, Republic of|Mexico|Philippines|Singapore|Spain|Taiwan|United Kingdom 1
United States|Argentina|Australia|Belgium|Canada|France|Germany|Italy|Netherlands|Spain|Sweden 1
United States|Argentina|Belgium|Brazil|Bulgaria|Canada|China|France|Germany|Greece|Hungary|India|Israel|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|Peru|Poland|Portugal|Romania|Russian Federation|Spain|Switzerland|Taiwan|Thailand|Turkey 1
United States|Argentina|Canada|Italy 1
United States|Australia|Austria|Belgium|Canada|France|Germany|Italy|Japan|Netherlands|Spain|Sweden|United Kingdom 1
United States|Australia|Austria|Canada|Denmark|France|Switzerland|United Kingdom 1
United States|Australia|Austria|France|Germany|Italy|Netherlands|Poland|South Africa|Spain|Switzerland|United Kingdom 1
United States|Australia|Belgium|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Poland|Singapore|Spain|Taiwan|United Kingdom 1
United States|Austria|Belgium|Canada|China|Colombia|Czechia|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Lebanon|Netherlands|Poland|Russian Federation|Saudi Arabia|Slovakia|South Africa|Spain|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Austria|Belgium|France|Germany|Italy|Netherlands|Spain|United Kingdom 1
United States|Austria|Canada|Denmark|France|Germany|Italy|Netherlands|Poland|Spain|United Kingdom 1
United States|Austria|Denmark 1
United States|Belgium|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|United Kingdom 1
United States|Belgium|France|Germany|Italy|Portugal|Spain|United Kingdom 1
United States|France|Germany|Hong Kong|Hungary|Italy|Netherlands|Spain|United Kingdom 1
United States|France|Italy|Spain|United Kingdom 1
United States|France|Spain|United Kingdom 1
United States|Spain 1

Sites per Study

Site_count Study_Count
1 130
2 18
3 16
4 8
5 13
6 1
7 6
8 2
9 7
10 10
11 1
12 3
13 3
14 1
16 2
17 2
18 1
19 1
20 1
21 1
22 3
24 1
26 2
27 1
32 1
37 1
38 1
39 1
40 1
42 1
54 1
57 1
61 1
82 1
86 1
97 1
102 1
112 1
113 1
145 1
323 1
366 1
394 1
405 1
434 1
499 1

Phase

Phase Study_Count
Phase 2 130
Phase 1 35
N/A 27
Phase 1/Phase 2 24
Phase 3 18
Early Phase 1 9
Phase 4 9
Phase 2/Phase 3 4

Number of Arms

Number_of_Arms Count_of_Studies
1 173
2 53
3 7
4 4
6 3
7 1
8 2
9 2
NA 11

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 10.00000 2.0000 10.00000 12.000 3.00000 26.00 11.0000 26
1st Qu. 10.00000 21.0000 17.00000 36.500 24.50000 46.25 75.5000 49
Median 20.00000 40.0000 29.00000 61.500 40.00000 126.50 208.5000 50
Mean 35.55556 115.4444 37.17143 121.375 83.07874 133.50 203.1667 113
3rd Qu. 30.00000 133.0000 48.00000 155.750 90.00000 213.75 301.5000 106
Max. 100.00000 1000.0000 122.00000 527.000 1499.00000 255.00 427.0000 413

Trial Group Type

group_type Group_Count
Experimental 334
Active Comparator 18
Other 11
NA 11
Placebo Comparator 10
No Intervention 2

Intervention Model

intervention_model Study_Count
Single Group Assignment 184
Parallel Assignment 56
Crossover Assignment 6
NA 5
Sequential Assignment 3
Factorial Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 206
Diagnostic 38
Supportive Care 4
Other 3
Basic Science 2
Prevention 2
Device Feasibility 1

Observational Studies

Studies by Country

Country Study_Count
United States 15
France 12
Netherlands 7
Canada 4
China 4
Italy 3
Spain 3
Sweden 3
United Kingdom 3
Austria|Germany|Switzerland 1
Belgium|France 1
Czechia|France|Hungary|Israel|Italy|Poland|Spain|United Kingdom 1
Denmark 1
Denmark|Estonia|Finland|Latvia|Lithuania|Norway|Sweden 1
Germany 1
NA 1
Poland 1
Portugal|Spain 1
Switzerland 1
Taiwan 1
United States|Portugal|United Kingdom 1

Sites per Study

Site_count Study_Count
1 47
2 2
3 2
5 2
8 1
10 1
12 2
17 1
22 1
24 1
28 1
32 1
35 1
43 1
55 1
57 1

Enrollment Metrics

Measure Observational
Min 13.0000
1st Qu 42.0000
Median 100.0000
Mean 208.6364
3rd Qu 199.7500
Max 2000.0000

Observation Model

observational_model Study_Count
Cohort 49
Case-Only 6
Case-Control 5
Other 5
NA 1

Time Perspective

time_perspective Study_Count
Prospective 36
Retrospective 15
Cross-Sectional 10
Other 4
NA 1

Registries

Studies by Country

Country Study_Count
United States 3
China 2
Canada 1
Denmark 1
Italy 1
Sweden 1

Sites per Study

Site_count Study_Count
1 7
8 1
75 1

Enrollment Metrics

Measure Registries
Min 40.0
1st Qu 120.0
Median 146.0
Mean 111757.2
3rd Qu 1500.0
Max 999999.0

Registry Model

observational_model Study_Count
Cohort 9

Time Perspective

time_perspective Study_Count
Prospective 9

Follow-up

target_duration Study_Count
4 Years 2
5 Years 2
12 Months 1
2 Days 1
3 Years 1
36 Months 1
80 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03095274 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin https://ClinicalTrials.gov/show/NCT03095274 Recruiting Grupo Espanol de Tumores Neuroendocrinos 2020-06-30
NCT02936323 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers https://ClinicalTrials.gov/show/NCT02936323 Active, not recruiting Tarveda Therapeutics 2020-07-31
NCT02685553 Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project https://ClinicalTrials.gov/show/NCT02685553 Completed Universita di Verona 2016-10-31
NCT03365791 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03365791 Active, not recruiting Novartis 2019-02-21
NCT04427787 A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET https://ClinicalTrials.gov/show/NCT04427787 Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 2023-11-30
NCT03375320 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT03375320 Recruiting National Cancer Institute (NCI) 2021-01-01
NCT03335670 Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03335670 Recruiting University of Iowa 2021-10-01
NCT03289741 A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide https://ClinicalTrials.gov/show/NCT03289741 Recruiting Memorial Sloan Kettering Cancer Center 2021-09-30
NCT03279601 Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor https://ClinicalTrials.gov/show/NCT03279601 Recruiting Peking University 2019-09-01
NCT03278379 Avelumab in G2-3 NET https://ClinicalTrials.gov/show/NCT03278379 Active, not recruiting Sunnybrook Health Sciences Centre 2020-01-11
NCT03278275 PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105 https://ClinicalTrials.gov/show/NCT03278275 Recruiting Rigshospitalet, Denmark 2020-12-31
NCT03273712 Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) https://ClinicalTrials.gov/show/NCT03273712 Recruiting University of Iowa 2020-01-31
NCT03271281 PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2 https://ClinicalTrials.gov/show/NCT03271281 Recruiting Rigshospitalet, Denmark 2020-09-01
NCT03220217 To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) https://ClinicalTrials.gov/show/NCT03220217 Completed Ipsen 2019-07-25
NCT03217097 MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents https://ClinicalTrials.gov/show/NCT03217097 Recruiting Hospices Civils de Lyon 2021-07-31
NCT03211988 Entinostat Neuroendocrine (NE) Tumor https://ClinicalTrials.gov/show/NCT03211988 Recruiting Columbia University 2019-08-31
NCT03206060 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma https://ClinicalTrials.gov/show/NCT03206060 Recruiting National Institutes of Health Clinical Center (CC) 2023-01-01
NCT03183271 Proton Boost for Locally Advanced HEAD AND NECK TUMORS https://ClinicalTrials.gov/show/NCT03183271 Completed CNAO National Center of Oncological Hadrontherapy 2015-03-30
NCT03167853 Study of JS001 in Patients With Advanced Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03167853 Completed Peking University 2018-12-11
NCT03147768 Laser Tissue Welding - Distal Pancreatectomy Sealing Study https://ClinicalTrials.gov/show/NCT03147768 Recruiting Laser Tissue Welding, Inc. 2020-07-01
NCT03145857 A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use https://ClinicalTrials.gov/show/NCT03145857 Recruiting AHS Cancer Control Alberta 2031-12-31
NCT03143946 DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor https://ClinicalTrials.gov/show/NCT03143946 Completed University Medical Center Groningen 2019-08-31
NCT03136328 Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan https://ClinicalTrials.gov/show/NCT03136328 Completed Montefiore Medical Center 2017-03-31
NCT03110978 Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03110978 Recruiting M.D. Anderson Cancer Center 2022-06-30
NCT03083210 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET https://ClinicalTrials.gov/show/NCT03083210 Recruiting Samsung Medical Center 2020-02-29
NCT03079440 TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03079440 Recruiting Asan Medical Center 2020-12-31
NCT03074513 Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors https://ClinicalTrials.gov/show/NCT03074513 Recruiting M.D. Anderson Cancer Center 2021-03-31
NCT03070301 A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03070301 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-02-28
NCT03049189 Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients https://ClinicalTrials.gov/show/NCT03049189 Recruiting ITM Solucin GmbH 2023-12-31
NCT03044977 Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03044977 Active, not recruiting University of Iowa 2020-12-31
NCT03042416 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety https://ClinicalTrials.gov/show/NCT03042416 Recruiting University of Alberta 2021-12-31
NCT03037385 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03037385 Recruiting Blueprint Medicines Corporation 2021-12-31
NCT03034200 Phase 2 Study of ONC201 in Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03034200 Recruiting Case Comprehensive Cancer Center 2020-09-30
NCT03012789 Surgical Intervention and the NETest https://ClinicalTrials.gov/show/NCT03012789 Active, not recruiting Wren Laboratories LLC 2021-12-31
NCT03001349 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03001349 Active, not recruiting M.D. Anderson Cancer Center 2020-12-31
NCT02955069 Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) https://ClinicalTrials.gov/show/NCT02955069 Completed Novartis 2018-08-10
NCT02943733 Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs https://ClinicalTrials.gov/show/NCT02943733 Recruiting University of Wisconsin, Madison 2021-08-31
NCT02939651 A Study of Pembrolizumab in Patients With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02939651 Active, not recruiting Fox Chase Cancer Center 2020-09-30
NCT02923934 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers https://ClinicalTrials.gov/show/NCT02923934 Active, not recruiting Olivia Newton-John Cancer Research Institute 2023-08-31
NCT02859064 Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres https://ClinicalTrials.gov/show/NCT02859064 Active, not recruiting SCRI Development Innovations, LLC 2020-04-30
NCT02842749 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China https://ClinicalTrials.gov/show/NCT02842749 Active, not recruiting Novartis 2024-12-02
NCT02840149 SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors https://ClinicalTrials.gov/show/NCT02840149 Enrolling by invitation Jewish General Hospital 2021-12-31
NCT02838342 Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02838342 Active, not recruiting Centre Hospitalier Universitaire de Besancon 2020-07-31
NCT02826928 Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02826928 Recruiting CHU de Reims 2022-10-31
NCT02823691 The MetNET-2 Trial https://ClinicalTrials.gov/show/NCT02823691 Recruiting National Cancer Institute, Milan 2022-04-30
NCT02806648 A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) https://ClinicalTrials.gov/show/NCT02806648 Completed Grupo Espanol de Tumores Neuroendocrinos 2017-07-31
NCT02754297 Personalized PRRT of Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02754297 Recruiting CHU de Quebec-Universite Laval 2021-04-30
NCT02749331 Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy https://ClinicalTrials.gov/show/NCT02749331 Recruiting Uppsala University 2022-08-31
NCT02743741 Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02743741 Recruiting University Health Network, Toronto 2024-01-31
NCT02736500 Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02736500 Active, not recruiting Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori 2018-07-31
NCT02736448 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02736448 Active, not recruiting Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori 2019-08-31
NCT02724540 Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver https://ClinicalTrials.gov/show/NCT02724540 Recruiting University of Pennsylvania 2023-03-31
NCT02713763 Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib https://ClinicalTrials.gov/show/NCT02713763 Completed Grupo Espanol de Tumores Neuroendocrinos 2019-10-23
NCT02698410 Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. https://ClinicalTrials.gov/show/NCT02698410 Completed Ipsen 2019-02-08
NCT02693067 A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver https://ClinicalTrials.gov/show/NCT02693067 Recruiting Provectus Pharmaceuticals 2020-07-31
NCT02683941 Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02683941 Active, not recruiting Ipsen 2020-02-28
NCT02678780 Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02678780 Completed Grupo Espanol de Tumores Neuroendocrinos 2017-12-31
NCT02651987 Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg https://ClinicalTrials.gov/show/NCT02651987 Completed Ipsen 2019-10-16
NCT02611024 Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors https://ClinicalTrials.gov/show/NCT02611024 Recruiting PharmaMar 2020-11-30
NCT02609737 Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02609737 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-11-30
NCT02592707 Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs https://ClinicalTrials.gov/show/NCT02592707 Active, not recruiting Ipsen 2022-05-31
NCT02589821 Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02589821 Active, not recruiting Hutchison Medipharma Limited 2020-03-30
NCT02589522 Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02589522 Recruiting National Cancer Institute (NCI) 2020-12-30
NCT02588170 Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02588170 Active, not recruiting Hutchison Medipharma Limited 2019-03-31
NCT01229943 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT01229943 Active, not recruiting National Cancer Institute (NCI) 2014-09-01
NCT02575300 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02575300 Completed H. Lee Moffitt Cancer Center and Research Institute 2019-03-26
NCT03197012 Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor https://ClinicalTrials.gov/show/NCT03197012 Completed University of California, San Francisco 2019-05-31
NCT03043664 Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03043664 Active, not recruiting Duke University 2020-09-30
NCT02893930 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT02893930 Active, not recruiting National Cancer Institute (NCI) 2020-07-31
NCT01253161 Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) https://ClinicalTrials.gov/show/NCT01253161 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2020-12-31
NCT00569127 Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor https://ClinicalTrials.gov/show/NCT00569127 Active, not recruiting National Cancer Institute (NCI) 2015-01-01
NCT02539433 Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA) https://ClinicalTrials.gov/show/NCT02539433 Completed Northwell Health 2015-05-31
NCT02489903 RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) https://ClinicalTrials.gov/show/NCT02489903 Active, not recruiting EpicentRx, Inc. 2020-12-31
NCT02489604 Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02489604 Active, not recruiting Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori 2020-12-31
NCT02481804 Optimal Feeding for NET Patients https://ClinicalTrials.gov/show/NCT02481804 Completed University Medical Center Groningen 2016-03-31
NCT02472678 Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor https://ClinicalTrials.gov/show/NCT02472678 Completed University Medical Center Groningen 2017-05-31
NCT02464007 Study of rSIFN-co for Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02464007 Active, not recruiting Sichuan Huiyang Life Science and Technology Corporation 2021-10-31
NCT02441088 Theranostics: 68GaDOTATOC and 90YDOTATOC https://ClinicalTrials.gov/show/NCT02441088 Active, not recruiting University of Iowa 2020-01-31
NCT02441062 Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02441062 Completed University of Iowa 2020-01-20
NCT02420691 Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin https://ClinicalTrials.gov/show/NCT02420691 Completed M.D. Anderson Cancer Center 2019-06-05
NCT02402920 Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02402920 Recruiting M.D. Anderson Cancer Center 2023-07-31
NCT02402062 A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours https://ClinicalTrials.gov/show/NCT02402062 Completed Grupo Espanol de Tumores Neuroendocrinos 2018-05-31
NCT02399215 Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02399215 Active, not recruiting Roswell Park Cancer Institute 2020-08-01
NCT02358356 Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study https://ClinicalTrials.gov/show/NCT02358356 Recruiting Australasian Gastro-Intestinal Trials Group 2018-12-31
NCT02355535 Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 https://ClinicalTrials.gov/show/NCT02355535 Recruiting Vanquish Oncology, Inc. 2019-12-31
NCT02348749 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies https://ClinicalTrials.gov/show/NCT02348749 Recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT02315625 Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery https://ClinicalTrials.gov/show/NCT02315625 Completed National Institutes of Health Clinical Center (CC) 2019-05-22
NCT02305810 A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus https://ClinicalTrials.gov/show/NCT02305810 Completed European Institute of Oncology 2017-01-12
NCT02299089 Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) https://ClinicalTrials.gov/show/NCT02299089 Completed Camurus AB 2016-05-31
NCT02288377 A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) https://ClinicalTrials.gov/show/NCT02288377 Completed Federation Francophone de Cancerologie Digestive 2020-01-31
NCT02279602 Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study https://ClinicalTrials.gov/show/NCT02279602 Completed Mateon Therapeutics 2016-08-31
NCT02267967 Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02267967 Completed Hutchison Medipharma Limited 2017-08-23
NCT02259725 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02259725 Active, not recruiting University of Southern California 2020-08-16
NCT02246127 Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrin Tumor (pNET) https://ClinicalTrials.gov/show/NCT02246127 Active, not recruiting Grupo Espanol de Tumores Neuroendocrinos 2019-12-31
NCT04452396 CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia https://ClinicalTrials.gov/show/NCT04452396 Recruiting Barts & The London NHS Trust 2020-11-18
NCT02231762 Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET https://ClinicalTrials.gov/show/NCT02231762 Completed Ipsen 2016-12-31
NCT02185443 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases https://ClinicalTrials.gov/show/NCT02185443 Recruiting University of Sao Paulo 2021-05-31
NCT02174549 Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer https://ClinicalTrials.gov/show/NCT02174549 Active, not recruiting Teclison Ltd. 2020-08-31
NCT02162446 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET https://ClinicalTrials.gov/show/NCT02162446 Completed Ipsen 2015-06-30
NCT02159989 Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT02159989 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT02132468 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers https://ClinicalTrials.gov/show/NCT02132468 Completed Mateon Therapeutics 2016-06-30
NCT02125929 Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms https://ClinicalTrials.gov/show/NCT02125929 Completed Peking Union Medical College Hospital 2014-12-31
NCT02125474 Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate https://ClinicalTrials.gov/show/NCT02125474 Completed Instituto Nacional de Cancerologia, Columbia 2019-10-31
NCT02113800 Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study https://ClinicalTrials.gov/show/NCT02113800 Recruiting AIO-Studien-gGmbH 2019-09-30
NCT02101918 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT02101918 Completed National Cancer Institute (NCI) 2018-01-31
NCT02077933 Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors https://ClinicalTrials.gov/show/NCT02077933 Completed Novartis 2019-04-12
NCT02075606 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients https://ClinicalTrials.gov/show/NCT02075606 Completed Ipsen 2017-06-30
NCT02067988 Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study https://ClinicalTrials.gov/show/NCT02067988 Completed UMC Utrecht 2019-09-01
NCT02063958 Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02063958 Completed Esanex Inc. 2017-03-27
NCT01317615 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation https://ClinicalTrials.gov/show/NCT01317615 Completed Novartis 2015-03-31
NCT01290536 Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases https://ClinicalTrials.gov/show/NCT01290536 Completed University of California, San Francisco 2013-10-31
NCT01280201 Pazopanib as Single Agent in Advanced NETs https://ClinicalTrials.gov/show/NCT01280201 Completed Grupo Espanol de Tumores Neuroendocrinos 2013-04-30
NCT01873248 Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients https://ClinicalTrials.gov/show/NCT01873248 Completed Jonsson Comprehensive Cancer Center 2017-06-16
NCT01869725 Ga-DOTATOC Versus Octreoscan + CT https://ClinicalTrials.gov/show/NCT01869725 Completed University of Iowa 2018-12-26
NCT01849523 Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study https://ClinicalTrials.gov/show/NCT01849523 Completed University Medical Center Groningen 2014-08-31
NCT01842165 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs https://ClinicalTrials.gov/show/NCT01842165 Recruiting Jules Bordet Institute 2019-06-30
NCT01841736 Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors https://ClinicalTrials.gov/show/NCT01841736 Active, not recruiting National Cancer Institute (NCI) 2019-03-05
NCT01824875 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01824875 Active, not recruiting Eastern Cooperative Oncology Group 2023-06-01
NCT01794793 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies https://ClinicalTrials.gov/show/NCT01794793 Active, not recruiting Novartis 2023-06-09
NCT01784861 VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01784861 Active, not recruiting Washington University School of Medicine 2020-09-30
NCT01747096 TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01747096 Completed Nantes University Hospital 2016-05-31
NCT01744249 Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas https://ClinicalTrials.gov/show/NCT01744249 Active, not recruiting Grupo Espanol de Tumores Neuroendocrinos 2020-11-30
NCT01730417 Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG https://ClinicalTrials.gov/show/NCT01730417 Completed Duke University 2011-06-30
NCT01678664 Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors https://ClinicalTrials.gov/show/NCT01678664 Completed Federation Francophone de Cancerologie Digestive 2018-09-30
NCT01673906 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours https://ClinicalTrials.gov/show/NCT01673906 Completed Arcispedale Santa Maria Nuova-IRCCS 2015-08-31
NCT01658436 BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. https://ClinicalTrials.gov/show/NCT01658436 Completed Novartis 2015-07-31
NCT01638533 Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction https://ClinicalTrials.gov/show/NCT01638533 Active, not recruiting National Cancer Institute (NCI) 2018-11-29
NCT01619865 Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors https://ClinicalTrials.gov/show/NCT01619865 Active, not recruiting University of Iowa 2017-08-27
NCT01595009 An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) https://ClinicalTrials.gov/show/NCT01595009 Completed Novartis 2016-08-09
NCT01590199 Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs https://ClinicalTrials.gov/show/NCT01590199 Completed Novartis 2018-09-11
NCT01578239 A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours https://ClinicalTrials.gov/show/NCT01578239 Active, not recruiting Advanced Accelerator Applications 2015-07-31
NCT01548482 Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT01548482 Completed National Cancer Institute (NCI) 2014-01-31
NCT03972488 Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET https://ClinicalTrials.gov/show/NCT03972488 Recruiting Advanced Accelerator Applications 2023-12-31
NCT01525550 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01525550 Completed Pfizer 2016-03-19
NCT01525082 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01525082 Active, not recruiting Stanford University 2018-01-31
NCT01524783 Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) https://ClinicalTrials.gov/show/NCT01524783 Active, not recruiting Novartis 2014-11-28
NCT01476592 A Biological Study of Resveratrol’s Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors https://ClinicalTrials.gov/show/NCT01476592 Completed University of Wisconsin, Madison 2013-10-31
NCT01469572 Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases https://ClinicalTrials.gov/show/NCT01469572 Completed Emory University 2018-10-31
NCT01465659 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT01465659 Active, not recruiting Northwestern University 2018-07-30
NCT01456078 A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01456078 Completed Lund University Hospital 2018-11-30
NCT01396382 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer https://ClinicalTrials.gov/show/NCT01396382 Completed Vanderbilt-Ingram Cancer Center 2014-05-31
NCT01384617 Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy https://ClinicalTrials.gov/show/NCT01384617 Completed Wakayama Medical University 2014-06-30
NCT01324492 Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor https://ClinicalTrials.gov/show/NCT01324492 Completed Novartis 2014-06-30
NCT04375267 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours https://ClinicalTrials.gov/show/NCT04375267 Recruiting Vastra Gotaland Region 2022-06-30
NCT04362436 TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets https://ClinicalTrials.gov/show/NCT04362436 Recruiting Imperial College London 2022-09-30
NCT04318561 Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT04318561 Recruiting Peking Union Medical College Hospital 2021-12-01
NCT04296149 Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe https://ClinicalTrials.gov/show/NCT04296149 Completed European Institute of Oncology 2018-12-31
NCT04258592 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT04258592 Recruiting Universitaire Ziekenhuizen Leuven 2021-06-01
NCT04207463 A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT04207463 Recruiting Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2020-12-31
NCT04197310 Cabozantinib and Nivolumab for Carcinoid Tumors https://ClinicalTrials.gov/show/NCT04197310 Recruiting Dana-Farber Cancer Institute 2021-12-26
NCT04194125 Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer https://ClinicalTrials.gov/show/NCT04194125 Recruiting University of Warmia and Mazury 2020-06-30
NCT04166006 A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers. https://ClinicalTrials.gov/show/NCT04166006 Recruiting Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori 2022-06-30
NCT04129255 Octreotide LAR in the Induction of Immunologic Response in NENs Patients https://ClinicalTrials.gov/show/NCT04129255 Active, not recruiting National Cancer Institute, Naples 2019-12-01
NCT04123262 Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression https://ClinicalTrials.gov/show/NCT04123262 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2022-06-30
NCT04104529 Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department https://ClinicalTrials.gov/show/NCT04104529 Recruiting Institut du Cancer de Montpellier - Val d’Aurelle 2024-10-31
NCT04074135 Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT04074135 Recruiting National Institutes of Health Clinical Center (CC) 2036-01-30
NCT04073017 Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency https://ClinicalTrials.gov/show/NCT04073017 Recruiting Vanderbilt-Ingram Cancer Center 2021-04-30
NCT04041882 68Ga-DOTATATE PET/CT in Neuroendocrine Tumor https://ClinicalTrials.gov/show/NCT04041882 Recruiting Peking Union Medical College Hospital 2020-12-30
NCT04040088 An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT04040088 Recruiting Mayo Clinic 2023-07-10
NCT04029428 Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression https://ClinicalTrials.gov/show/NCT04029428 Recruiting University of Warmia and Mazury 2021-01-01
NCT03986593 Cryoablation of Bone Metastases From Endocrine Tumors https://ClinicalTrials.gov/show/NCT03986593 Recruiting Instituto do Cancer do Estado de São Paulo 2021-06-15
NCT03980925 Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. https://ClinicalTrials.gov/show/NCT03980925 Recruiting Grupo Espanol de Tumores Neuroendocrinos 2021-09-30
NCT03950609 Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors https://ClinicalTrials.gov/show/NCT03950609 Recruiting M.D. Anderson Cancer Center 2021-05-07
NCT03935893 Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers https://ClinicalTrials.gov/show/NCT03935893 Recruiting University of Pittsburgh 2029-06-01
NCT03910660 A Trial of BXCL701 and Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer https://ClinicalTrials.gov/show/NCT03910660 Recruiting BioXcel Therapeutics Inc 2022-04-02
NCT03891784 Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03891784 Recruiting University of Washington 2023-09-30
NCT03883776 Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03883776 Completed Universitaire Ziekenhuizen Leuven 2019-10-29
NCT03881306 DEBOXA for Inoperable NET Liver Metastases https://ClinicalTrials.gov/show/NCT03881306 Recruiting Xiangya Hospital of Central South University 2020-12-31
NCT03879694 Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03879694 Recruiting Roswell Park Cancer Institute 2020-07-17
NCT03873870 68Ga-DOTATATE PET for Management of Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03873870 Recruiting University Health Network, Toronto 2024-04-01
NCT03834701 Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms https://ClinicalTrials.gov/show/NCT03834701 Recruiting Catholic University of the Sacred Heart 2021-06-01
NCT03734913 A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03734913 Recruiting Guangdong Zhongsheng Pharmaceutical Co., Ltd. 2020-11-01
NCT03728361 Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer https://ClinicalTrials.gov/show/NCT03728361 Recruiting Ohio State University Comprehensive Cancer Center 2021-12-31
NCT03724409 Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases https://ClinicalTrials.gov/show/NCT03724409 Recruiting University of Iowa 2025-12-31
NCT03722511 Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs https://ClinicalTrials.gov/show/NCT03722511 Recruiting University of Kentucky 2020-08-31
NCT03673943 Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE https://ClinicalTrials.gov/show/NCT03673943 Completed Radiomedix, Inc. 2019-03-23
NCT03670030 A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System https://ClinicalTrials.gov/show/NCT03670030 Recruiting Ochsner Health System 2020-05-01
NCT03667092 Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor https://ClinicalTrials.gov/show/NCT03667092 Recruiting University Hospital, Toulouse 2021-08-31
NCT03629847 Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue https://ClinicalTrials.gov/show/NCT03629847 Recruiting King Faisal Specialist Hospital & Research Center 2018-12-31
NCT03600233 Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03600233 Recruiting TaiRx, Inc. 2021-11-30
NCT03591731 Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) https://ClinicalTrials.gov/show/NCT03591731 Recruiting Intergroupe Francophone de Cancerologie Thoracique 2021-10-31
NCT03590119 Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases https://ClinicalTrials.gov/show/NCT03590119 Recruiting UMC Utrecht 2021-09-01
NCT03582475 Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate https://ClinicalTrials.gov/show/NCT03582475 Recruiting Jonsson Comprehensive Cancer Center 2020-09-01
NCT03511768 A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms https://ClinicalTrials.gov/show/NCT03511768 Recruiting Xiangya Hospital of Central South University 2019-12-30
NCT03478358 Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03478358 Recruiting Peking Union Medical College Hospital 2019-12-01
NCT03475953 A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors https://ClinicalTrials.gov/show/NCT03475953 Recruiting Institut Bergonié 2020-11-30
NCT03466216 Phase 1 Study of AlphaMedixâ„¢ in Adult Subjects With SSTR (+) NET https://ClinicalTrials.gov/show/NCT03466216 Recruiting Radiomedix, Inc. 2020-07-31
NCT03457948 Pembrolizumab in With Liver-Directed or Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors With Metastases https://ClinicalTrials.gov/show/NCT03457948 Recruiting University of California, San Francisco 2020-11-30
NCT03454763 Optimizing the Interval Between Cycles of PRRT With 177lu-dotatate in sstr2 Positive Tumors https://ClinicalTrials.gov/show/NCT03454763 Recruiting Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori 2021-05-31
NCT03453489 AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm https://ClinicalTrials.gov/show/NCT03453489 Recruiting Barbara Ann Karmanos Cancer Institute 2020-06-01
NCT03422029 Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients https://ClinicalTrials.gov/show/NCT03422029 Recruiting Peking University 2020-12-30
NCT03420521 Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03420521 Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2023-01-15
NCT03411915 A Study of XmAb®18087 in Subjects With NET and GIST https://ClinicalTrials.gov/show/NCT03411915 Recruiting Xencor, Inc. 2021-03-31
NCT01263353 Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs https://ClinicalTrials.gov/show/NCT01263353 Completed Novartis 2014-03-31
NCT01262235 A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients https://ClinicalTrials.gov/show/NCT01262235 Completed Arbutus Biopharma Corporation 2015-07-31
NCT01218555 Study of Everolimus (RAD001) in Combination With Lenalidomide https://ClinicalTrials.gov/show/NCT01218555 Completed Emory University 2017-05-31
NCT01204476 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT01204476 Completed National Cancer Institute (NCI) 2014-07-31
NCT01177397 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT01177397 Completed Celgene 2016-11-15
NCT01169649 Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) https://ClinicalTrials.gov/show/NCT01169649 Completed Memorial Sloan Kettering Cancer Center 2014-02-28
NCT01121562 Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01121562 Completed Pfizer 2011-07-31
NCT01099540 Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor https://ClinicalTrials.gov/show/NCT01099540 Completed Samsung Medical Center 2012-03-31
NCT01099228 Combination Targeted Radiotherapy in Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01099228 Completed University of Iowa 2008-04-30
NCT01024387 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01024387 Completed Dana-Farber Cancer Institute 2016-01-31
NCT01010126 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer https://ClinicalTrials.gov/show/NCT01010126 Completed National Cancer Institute (NCI) 2017-03-13
NCT00990535 High Dose Somatostatin Analogues in Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00990535 Completed Federico II University 2007-12-31
NCT00978211 DOTA-TOC in Metastasized Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00978211 Completed University Hospital, Basel, Switzerland 2013-09-30
NCT00965250 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy https://ClinicalTrials.gov/show/NCT00965250 Completed National Institutes of Health Clinical Center (CC) 2012-03-31
NCT00953394 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00953394 Completed University of Turin, Italy 2006-02-28
NCT00942682 Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00942682 Completed Dana-Farber Cancer Institute 2013-03-31
NCT03870399 Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression https://ClinicalTrials.gov/show/NCT03870399 Recruiting AC Camargo Cancer Center 2022-03-13
NCT00869050 Capecitabine and Temozolomide for Neuroendocrine Cancers https://ClinicalTrials.gov/show/NCT00869050 Completed Columbia University 2013-12-31
NCT00843531 RAD001 and Erlotinib in Patients With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00843531 Completed University of California, San Francisco 2013-07-31
NCT04440956 An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours https://ClinicalTrials.gov/show/NCT04440956 Completed Clarity Pharmaceuticals Ltd 2016-02-25
NCT04385992 Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET https://ClinicalTrials.gov/show/NCT04385992 Recruiting IRCCS San Raffaele 2021-11-30
NCT01970540 Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors https://ClinicalTrials.gov/show/NCT01970540 Completed PharmaMar 2017-08-09
NCT01364415 Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) https://ClinicalTrials.gov/show/NCT01364415 Completed Novartis 2016-04-30
NCT03981614 Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer https://ClinicalTrials.gov/show/NCT03981614 Recruiting Academic and Community Cancer Research United 2020-12-28
NCT00804336 Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00804336 Completed Dana-Farber Cancer Institute 2014-09-30
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) https://ClinicalTrials.gov/show/NCT02568267 Recruiting Hoffmann-La Roche 2022-12-01
NCT01466036 Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors https://ClinicalTrials.gov/show/NCT01466036 Active, not recruiting Dana-Farber Cancer Institute 2020-09-30
NCT04079712 Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT04079712 Recruiting National Cancer Institute (NCI) 2021-10-01
NCT01967537 Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01967537 Completed National Institutes of Health Clinical Center (CC) 2017-12-17
NCT01845675 Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor https://ClinicalTrials.gov/show/NCT01845675 Completed Peking Union Medical College Hospital 2016-11-30
NCT04077372 Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers https://ClinicalTrials.gov/show/NCT04077372 Recruiting Stanford University 2020-09-30
NCT00781911 A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer https://ClinicalTrials.gov/show/NCT00781911 Completed Eli Lilly and Company 2011-07-31
NCT00780663 Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT00780663 Completed Cylene Pharmaceuticals 2010-03-31
NCT00688623 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe https://ClinicalTrials.gov/show/NCT00688623 Completed Novartis 2016-11-07
NCT00681187 Somatuline Autogel Preference and Health Economy Study https://ClinicalTrials.gov/show/NCT00681187 Completed Ipsen 2010-08-31
NCT00610129 Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) https://ClinicalTrials.gov/show/NCT00610129 Completed Memorial Sloan Kettering Cancer Center 2010-01-31
NCT00605566 Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00605566 Completed University Health Network, Toronto 2015-02-28
NCT00602082 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00602082 Completed National Cancer Institute (NCI) 2009-12-31
NCT00590343 Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00590343 Completed Louisiana State University Health Sciences Center in New Orleans 2010-03-31
NCT00576680 RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00576680 Active, not recruiting Dana-Farber Cancer Institute 2019-08-31
NCT00510068 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00510068 Completed Novartis 2010-02-28
NCT00454363 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer https://ClinicalTrials.gov/show/NCT00454363 Completed National Cancer Institute (NCI) 2014-03-31
NCT00442533 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00442533 Completed Radio Isotope Therapy of America 2014-08-30
NCT00434109 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization https://ClinicalTrials.gov/show/NCT00434109 Completed H. Lee Moffitt Cancer Center and Research Institute 2012-02-29
NCT00428220 A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. https://ClinicalTrials.gov/show/NCT00428220 Completed Pfizer 2014-08-31
NCT00427349 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00427349 Completed Eastern Cooperative Oncology Group 2014-10-31
NCT00424723 Pemetrexed in Patients With Advanced Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00424723 Completed Dana-Farber Cancer Institute 2007-01-31
NCT00398320 Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00398320 Completed Stanford University 2012-10-31
NCT00363051 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy https://ClinicalTrials.gov/show/NCT00363051 Completed Novartis 2008-01-31
NCT00326469 Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours https://ClinicalTrials.gov/show/NCT00326469 Completed Ipsen 2009-11-30
NCT00230139 SPECT/CT in Endocrine and Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00230139 Completed Rambam Health Care Campus 2004-01-31
NCT00171873 Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut https://ClinicalTrials.gov/show/NCT00171873 Completed Philipps University Marburg Medical Center 2008-06-30
NCT00165230 Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00165230 Completed Dana-Farber Cancer Institute 2006-07-31
NCT00137774 Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00137774 Completed Dana-Farber Cancer Institute 2005-07-31
NCT00131911 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00131911 Completed National Cancer Institute (NCI) 2010-10-31
NCT00017199 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00017199 Completed National Cancer Institute (NCI) NA
NCT00075439 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00075439 Completed National Cancer Institute (NCI) 2007-05-31
NCT00004922 Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00004922 Completed Memorial Sloan Kettering Cancer Center 2002-06-30
NCT00056693 Treatment With SU11248 in Patients With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00056693 Completed Pfizer 2006-09-30
NCT00027638 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00027638 Completed Memorial Sloan Kettering Cancer Center 2003-12-31
NCT00050349 EPO906 in Carcinoid and Other Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00050349 Completed Novartis 2007-04-30
NCT00037869 High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00037869 Completed M.D. Anderson Cancer Center 2005-01-31
NCT00501540 Lithium for Low-Grade Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00501540 Completed University of Wisconsin, Madison 2009-06-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04444401 Registry on NEN Patients and COVID-19 https://ClinicalTrials.gov/show/NCT04444401 Recruiting European Institute of Oncology 2020-12-31
NCT02586844 Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02586844 Active, not recruiting University Health Network, Toronto 2020-10-31
NCT03372356 Psychosocial Screening for Neuroendocrine Tumor Patients https://ClinicalTrials.gov/show/NCT03372356 Recruiting Peking University 2019-08-09
NCT03328065 Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer of the Colon, Stomach, Bile Ducts, Rectum or Lung, or Gastrointestinal Neuroendocrine Tumours https://ClinicalTrials.gov/show/NCT03328065 Recruiting Centre Hospitalier Universitaire Dijon 2020-12-31
NCT03220087 Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain https://ClinicalTrials.gov/show/NCT03220087 Completed Ipsen 2018-04-30
NCT03130205 Biomarker Study in Pancreatic Neuroendocrine Tumours https://ClinicalTrials.gov/show/NCT03130205 Recruiting Uppsala University 2021-01-01
NCT03112694 Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03112694 Completed Ipsen 2017-11-02
NCT03053999 Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) https://ClinicalTrials.gov/show/NCT03053999 Recruiting M.D. Anderson Cancer Center 2022-10-31
NCT03048266 Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients https://ClinicalTrials.gov/show/NCT03048266 Recruiting M.D. Anderson Cancer Center 2025-11-01
NCT03043508 Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) https://ClinicalTrials.gov/show/NCT03043508 Active, not recruiting M.D. Anderson Cancer Center 2025-04-01
NCT03022188 Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma https://ClinicalTrials.gov/show/NCT03022188 Recruiting Société Française d’Endoscopie Digestive 2022-01-31
NCT02948946 Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02948946 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2018-08-24
NCT02853422 Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours https://ClinicalTrials.gov/show/NCT02853422 Completed Ipsen 2017-01-31
NCT02841865 Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria https://ClinicalTrials.gov/show/NCT02841865 Completed Grupo Espanol de Tumores Neuroendocrinos 2017-12-31
NCT02788565 Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours https://ClinicalTrials.gov/show/NCT02788565 Completed Ipsen 2016-10-31
NCT02730104 Community-based Neuroendocrine Tumor (NET) Research Study https://ClinicalTrials.gov/show/NCT02730104 Completed Ipsen 2020-05-13
NCT02646644 Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis https://ClinicalTrials.gov/show/NCT02646644 Completed University Medical Center Groningen 2017-05-31
NCT02630654 Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs https://ClinicalTrials.gov/show/NCT02630654 Active, not recruiting Ipsen 2022-02-28
NCT02146170 Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors https://ClinicalTrials.gov/show/NCT02146170 Recruiting National Institutes of Health Clinical Center (CC) 2024-04-30
NCT02507908 5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor’ https://ClinicalTrials.gov/show/NCT02507908 Completed University Medical Center Groningen 2017-05-31
NCT02282059 The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02282059 Recruiting Pfizer 2022-12-12
NCT02264665 OPALINE : A Study Of Morbidity And Mortality At 2 Years https://ClinicalTrials.gov/show/NCT02264665 Completed Pfizer 2019-11-18
NCT02147106 Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study https://ClinicalTrials.gov/show/NCT02147106 Completed University Medical Center Groningen 2017-03-31
NCT02134639 PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation https://ClinicalTrials.gov/show/NCT02134639 Completed University Hospital, Bordeaux 2014-12-31
NCT02102893 Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan https://ClinicalTrials.gov/show/NCT02102893 Enrolling by invitation National Health Research Institutes, Taiwan 2019-02-28
NCT02092714 Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02092714 Active, not recruiting Fox Chase Cancer Center 2018-04-11
NCT01840449 Somatuline Predictive Factors in Acromegaly and NET https://ClinicalTrials.gov/show/NCT01840449 Completed Ipsen 2016-07-31
NCT01763554 Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014 https://ClinicalTrials.gov/show/NCT01763554 Active, not recruiting AHS Cancer Control Alberta 2023-12-31
NCT01603004 Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01603004 Completed Memorial Sloan Kettering Cancer Center 2019-06-24
NCT01423734 The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases https://ClinicalTrials.gov/show/NCT01423734 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-08-31
NCT01398306 Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. https://ClinicalTrials.gov/show/NCT01398306 Completed University Medical Center Groningen 2012-04-30
NCT01338090 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01338090 Completed University Medical Center Groningen 2012-03-31
NCT04331912 PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment https://ClinicalTrials.gov/show/NCT04331912 Active, not recruiting University of Warmia and Mazury 2022-12-31
NCT04134832 Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region https://ClinicalTrials.gov/show/NCT04134832 Recruiting University Hospital, Strasbourg, France 2020-06-30
NCT04090034 Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT04090034 Enrolling by invitation Methodist Health System 2026-06-30
NCT04085211 Image-Enhanced Endoscopy in the Gastrointestinal Tract https://ClinicalTrials.gov/show/NCT04085211 Recruiting King’s College Hospital NHS Trust 2022-02-28
NCT04045834 Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia https://ClinicalTrials.gov/show/NCT04045834 Recruiting Wuhan Union Hospital, China 2020-12-31
NCT03967951 CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms https://ClinicalTrials.gov/show/NCT03967951 Completed IRCCS San Raffaele 2019-05-06
NCT03958188 PreOPerative Imaging of NeuroEndocrine Tumors https://ClinicalTrials.gov/show/NCT03958188 Active, not recruiting Hospices Civils de Lyon 2019-06-30
NCT03948841 Measurement Variability of Liver Metastases From Neuroendocrine Tumors on Different Magnetic Resonance Imaging Sequences https://ClinicalTrials.gov/show/NCT03948841 Completed CHU de Reims 2012-12-01
NCT03947762 Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. https://ClinicalTrials.gov/show/NCT03947762 Recruiting Ipsen 2023-01-31
NCT03863106 The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours https://ClinicalTrials.gov/show/NCT03863106 Recruiting Hospices Civils de Lyon 2019-07-31
NCT03840720 The Patient’s Journey - the Time to Final Diagnosis in Patients With SiNET https://ClinicalTrials.gov/show/NCT03840720 Completed Vastra Gotaland Region 2019-07-31
NCT03840460 A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers https://ClinicalTrials.gov/show/NCT03840460 Recruiting Royal Marsden NHS Foundation Trust 2023-01-10
NCT03812939 Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs https://ClinicalTrials.gov/show/NCT03812939 Recruiting Peking Union Medical College Hospital 2019-12-31
NCT03017690 Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) https://ClinicalTrials.gov/show/NCT03017690 Completed Ipsen 2018-05-30
NCT03791346 Pancreatectomy for NET: External Evaluation of WHO 2017 Grading System https://ClinicalTrials.gov/show/NCT03791346 Completed University Hospital, Montpellier 2017-12-01
NCT03691064 Post-Authorization Long-Term Safety Study of LUTATHERA https://ClinicalTrials.gov/show/NCT03691064 Recruiting Advanced Accelerator Applications 2024-12-31
NCT03689231 Volumetric Imaging Follow up of Patients With Liver Metastases of Small Intestinal Neuroendocrine Tumors (NETs). https://ClinicalTrials.gov/show/NCT03689231 Active, not recruiting Hospices Civils de Lyon 2018-08-30
NCT03645915 GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03645915 Completed Centre Hospitalier Universitaire, Amiens 2016-11-13
NCT03592940 The Management of Neuroendocrine Tumours: A Nutritional Viewpoint. https://ClinicalTrials.gov/show/NCT03592940 Completed Federico II University 2017-12-01
NCT03583528 DOTATOC PET/CT for Imaging NET Patients https://ClinicalTrials.gov/show/NCT03583528 Recruiting British Columbia Cancer Agency 2023-12-31
NCT03576040 Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03576040 Recruiting University Hospital, Brest 2023-07-31
NCT03562091 Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel https://ClinicalTrials.gov/show/NCT03562091 Recruiting Ipsen 2020-06-30
NCT03442959 Resection of the Primary Tumor vs no Resection in Asymptomatic Patients With Unresectable Synchronous Liver Metastases From siNEN https://ClinicalTrials.gov/show/NCT03442959 Recruiting CHU de Reims 2024-07-03
NCT01234168 A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea https://ClinicalTrials.gov/show/NCT01234168 Completed Ipsen 2012-12-31
NCT01135849 B-Receptor Signaling in Cardiomyopathy https://ClinicalTrials.gov/show/NCT01135849 Completed Stanford University 2010-10-31
NCT01039922 SwissNET - a Registry for Neuroendocrine Tumours in Switzerland https://ClinicalTrials.gov/show/NCT01039922 Recruiting University Hospital Inselspital, Berne 2028-01-31
NCT00970970 Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease https://ClinicalTrials.gov/show/NCT00970970 Completed University Medical Center Groningen 2012-11-30
NCT00923026 Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies https://ClinicalTrials.gov/show/NCT00923026 Enrolling by invitation National Institutes of Health Clinical Center (CC) NA
NCT04017104 Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging https://ClinicalTrials.gov/show/NCT04017104 Recruiting British Columbia Cancer Agency 2022-08-01
NCT02815969 The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02815969 Completed University Medical Center Groningen 2019-08-31
NCT00815620 Best Therapy for Patients With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00815620 Completed Zentralklinik Bad Berka 2016-08-31
NCT00789841 Gastrointestinal Motility in Patients With Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00789841 Completed University of Aarhus 2010-05-31
NCT00747786 Non Interventional Post Marketing Programme in Neuroendocrine Tumours https://ClinicalTrials.gov/show/NCT00747786 Completed Ipsen 2013-04-30
NCT00745381 A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00745381 Recruiting Memorial Sloan Kettering Cancer Center 2020-08-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03288597 Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms https://ClinicalTrials.gov/show/NCT03288597 Recruiting Peking University 2018-09-01
NCT02973204 Circulating Tumor Cells and Tumor DNA in HCC and NET https://ClinicalTrials.gov/show/NCT02973204 Recruiting University of Aarhus 2019-10-31
NCT02810600 Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors https://ClinicalTrials.gov/show/NCT02810600 Recruiting Centre de recherche du Centre hospitalier universitaire de Sherbrooke 2022-06-30
NCT02270567 RegisterNET - A Registry for Neuroendocrine Tumors in the USA https://ClinicalTrials.gov/show/NCT02270567 Active, not recruiting Wren Laboratories LLC 2018-03-31
NCT02012699 Integrated Cancer Repository for Cancer Research https://ClinicalTrials.gov/show/NCT02012699 Recruiting University of Nebraska 2099-12-31
NCT04282083 Database ITANET - ENETS Registry https://ClinicalTrials.gov/show/NCT04282083 Recruiting Italian Association Neuroendocrine Tumors 2020-09-30
NCT04066322 Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment https://ClinicalTrials.gov/show/NCT04066322 Recruiting Fudan University 2024-07-25
NCT03741517 Biomarker Study of Pancreatic Neuroendocrine Tumours https://ClinicalTrials.gov/show/NCT03741517 Recruiting Uppsala University 2022-12-31
NCT03452774 SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry https://ClinicalTrials.gov/show/NCT03452774 Recruiting Massive Bio, Inc. 2021-12-31